Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1491990
This article is part of the Research Topic EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects View all 10 articles

Comparative Safety Profile of Tyrosine Kinase Inhibitors in NSCLC: A Network Meta-Analysis of Hypertension and Thrombotic Risks

Provisionally accepted
Mingming Tan Mingming Tan 1Chenwei Pu Chenwei Pu 1Zhenzhen Wang Zhenzhen Wang 2Chengwei Jin Chengwei Jin 3*
  • 1 Department of Respiratory and Critical Care Medicine, Zibo Central Hospital, Shandong, China
  • 2 Department of Infectious Diseases, Zibo Central Hospital, Shandong, China
  • 3 Department of Cardiology, Zibo Central Hospital, Shandong, China

The final, formatted version of the article will be published soon.

    Background: This study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs).Objective: To compare the safety profiles of TKIs used in NSCLC treatment, focusing on hypertension and thrombotic risks.A comprehensive search identified randomized controlled trials evaluating the effects of TKIs in NSCLC patients. Bayesian network meta-analysis was employed to construct a comparative network of treatments.Results: Thirty studies involving 11,375 patients were included. Erlotinib had the lowest incidence of hypertension (SUCRA: 91.1%), followed by chemotherapy (88.8%). For thrombotic events, Erlotinib had the lowest risk (SUCRA: 66.1%), while Anlotinib and Cabozantinib had the highest thrombotic risks (SUCRA: 26.9%).Conclusions: Erlotinib presents the lowest risk for hypertension and thrombotic events, making it a preferred choice for NSCLC patients with cardiovascular concerns. Systematic review registration: https://www.crd.york.ac.uk/prospero, identifier CRD42024530770.

    Keywords: Non-small cell lung cancer, tyrosine kinase inhibitors, Hypertension, thrombotic events, Network meta-analysis, NSCLC

    Received: 05 Sep 2024; Accepted: 09 Jan 2025.

    Copyright: © 2025 Tan, Pu, Wang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chengwei Jin, Department of Cardiology, Zibo Central Hospital, Shandong, 255000, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.